| __timestamp | Mesoblast Limited | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 5078000000 |
| Thursday, January 1, 2015 | 65378000 | 4717000000 |
| Friday, January 1, 2016 | 52263000 | 5096000000 |
| Sunday, January 1, 2017 | 35072000 | 4986000000 |
| Monday, January 1, 2018 | 27415000 | 4214000000 |
| Tuesday, January 1, 2019 | 36983000 | 3806000000 |
| Wednesday, January 1, 2020 | 50918000 | 3671000000 |
| Friday, January 1, 2021 | 63586000 | 3528000000 |
| Saturday, January 1, 2022 | 57967000 | 3445000000 |
| Sunday, January 1, 2023 | 53107000 | 3498000000 |
| Monday, January 1, 2024 | 23626000 | 3702000000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing costs is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Mesoblast Limited from 2014 to 2023. Teva, a giant in the industry, consistently reported SG&A expenses in the billions, peaking in 2014 with over $5 billion. However, by 2023, these expenses had decreased by approximately 31%, reflecting strategic cost management.
In contrast, Mesoblast, a smaller player, showed a different trend. Their SG&A expenses fluctuated, peaking in 2015 with a 20% increase from the previous year, before gradually declining. By 2023, their expenses had dropped by about 64% from their peak. This data highlights the contrasting financial strategies of a large pharmaceutical company versus a smaller biotech firm, offering insights into their operational efficiencies and market challenges.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited and United Therapeutics Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Breaking Down Revenue Trends: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Breaking Down SG&A Expenses: Mesoblast Limited vs Galapagos NV